Opdivo in combo with Yervoy for Renal Cell Carcinoma – Details


( Last Updated : November 16, 2018)
Generic Name:
Nivolumab in combination with Ipilimumab
Project Status:
Complete
Therapeutic Area:
Advanced or Metastatic Renal Cell Carcinoma (RCC).
Manufacturer:
Bristol-Myers Squibb
Brand Name:
Opdivo in combination with Yervoy
Project Line:
Reimbursement Review
Project Number:
PC0132-000
NOC Date:

Details


Strength:
10 mg/mL
Tumour Type:
Genitourinary
Indications:
Renal Cell Carcinoma
Funding Request:
Intermediate/poor risk patients with previously untreated, advanced or metastatic renal cell carcinoma (RCC)
Review Status:
Complete
Pre Noc Submission:
Yes
Sponsor:
Bristol-Myers Squibb
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Requested and Granted
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.